Search Results - "Vulsteke, C."

ASO Author Reflections: Quantifying the Unseen: Years of Life Lost as a Patient-Centered Metric in Advanced Bladder Cancer.

Authors: Longoni M Falkenbach F Marmiroli A et al.

Source: Annals of surgical oncology [Ann Surg Oncol] 2026 Jun 29. Date of Electronic Publication: 2026 Jun 29.

Publication Type: Journal Article

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: MEDLINE

AUTHOR INDEX.

Source: Asia Pacific Journal of Clinical Oncology. Oct2021 Supplement S1, Vol. 17, p80-82. 3p.

Author Index.

Source: Asia Pacific Journal of Clinical Oncology. Nov2019 Supplement S9, Vol. 15, p213-223. 11p.

Meta-analysis of genome-wide association studies for cancer therapy-related cardiovascular dysfunction and functional mapping highlight an intergenic region close to TP63.

Authors: Martínez-Campelo, L. Blanco-Verea, A. López-Fernández, T. et al.

Source: Scientific Reports. 8/8/2024, Vol. 14 Issue 1, p1-10. 10p.

Urothelial Carcinoma of the Bladder with a Single Pancreatic Metastasis: A Case Report.

Authors: Calabrese, Benedetto Frego, Nicola Fasulo, Vittorio et al.

Source: Reports (MDPI AG). Mar2026, Vol. 9 Issue 1, p81. 7p.

Targeting Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma: Rationale, Current Evidence, and a CEACAM6 CAR-T Strategy.

Authors: Piejko, Marcin Bak, Karolina Wierciak, Joanna et al.

Source: Cancers. Jun2026, Vol. 18 Issue 11, p1852. 20p.

FGFR3 Alterations and Nectin-4 Expression as Therapeutic Biomarkers in Bladder Cancer: A Systematic Review and Single-Arm Meta-Analysis.

Authors: Antonov, Petar Raycheva, Gabriela Eshrefov, Denis et al.

Source: International Journal of Molecular Sciences. Jun2026, Vol. 27 Issue 11, p5007. 25p.

Immunotherapy for Upper Tract Urothelial Carcinomas: A 2026 Update.

Authors: Giannakodimos, Ilias Ziogou, Afroditi Grigoriou, Foteini et al.

Source: Cancers. May2026, Vol. 18 Issue 10, p1643. 15p.

Impact of Antidiabetic Medication on Therapy Outcomes in Metastatic Urothelial Cancer Patients Receiving Enfortumab Vedotin Monotherapy.

Authors: Schneidewind, Laila Kiss, Bernhard Zengerling, Friedemann et al.

Source: Biologics. Sep2025, Vol. 5 Issue 3, p20. 10p.

Identification of a Muscle-Invasive Bladder Carcinoma Molecular Subtype of Poor Responders to Neoadjuvant Chemotherapy and High Expression of Targetable Biomarkers.

Authors: Trilla-Fuertes, Lucía Pedregosa-Barbas, Jorge García-Fernández, Eugenia et al.

Source: International Journal of Molecular Sciences. Jan2026, Vol. 27 Issue 1, p476. 17p.

HCN2 Promotes BGN Transcription via REST to Regulate Ferroptosis and Tumor Progression in Bladder Cancer.

Authors: Cao, Yudong Ma, Jinchao Tang, Xingxing et al.

Source: International Journal of Molecular Sciences. Apr2026, Vol. 27 Issue 8, p3433. 16p.

A Rare Case of Descending Colon Metastasis Following Radical Nephroureterectomy for Left Ureteral Carcinoma: A Case Report and Literature Review.

Authors: Zhang, Huaiwen Liu, Heyang Luo, Yousong et al.

Source: Current Oncology. Apr2026, Vol. 33 Issue 4, p235. 12p.

Preliminary biological evaluation of a [¹⁷⁷Lu]Lu-labeled peptide targeting Nectin-4.

Authors: Li, Dengke Zhang, Yu Mu, Chao et al.

Source: EJNMMI Radiopharmacy & Chemistry. 3/30/2026, Vol. 11 Issue 1, p1-15. 15p.

Bladder Preservation with Concurrent Chemoradiotherapy Following Complete Response to Induction Systemic Therapy in Patients with Muscle-Invasive Bladder Cancer: A Review of the Existing Literature.

Authors: Ntoumas, Georgios Nikiforos Kougioumtzopoulou, Andromachi Desse, Dimitra et al.

Source: Cancers. Mar2026, Vol. 18 Issue 6, p961. 20p.

Predictors of Immune-Related Cardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Cohort Study.

Authors: Pătru, Ileana-Raluca Ionescu, Andreea-Iuliana Negru, Alina Gabriela et al.

Source: Journal of Clinical Medicine. Mar2026, Vol. 15 Issue 5, p1763. 17p.

Real-World Safety and Early Effectiveness of First-Line Enfortumab Vedotin Plus Pembrolizumab with Routine Dexamethasone Premedication in Advanced Urothelial Carcinoma.

Authors: Hara, Takuto Wakita, Naoto Tobe, Taisuke et al.

Source: Cancers. Mar2026, Vol. 18 Issue 5, p739. 13p.

Outcomes with Avelumab Maintenance Treatment for Advanced Urothelial Cancer in a US Patient Cohort.

Authors: Carson, Kenneth Mahmoudpour, Seyed Hamidreza Ike, Chiemeka et al.

Source: Current Oncology. Mar2026, Vol. 31 Issue 3, p138. 12p.

Current Landscape and Evolving Role of Targeted Agents in Urothelial Carcinoma.

Authors: Sammarco, Enrico Pellino, Antonio Bona, Eleonora et al.

Source: Cancers. Feb2026, Vol. 18 Issue 3, p409. 18p.

Pharmacogenomics of Antineoplastic Therapy in Children: Genetic Determinants of Toxicity and Efficacy.

Authors: Dushimova, Zaure Saliev, Timur Bazarbayeva, Aigul et al.

Source: Pharmaceutics. Feb2026, Vol. 18 Issue 2, p165. 13p.

Does the B7-H3 Immune Checkpoint Have High Potential as a Therapeutic Target?

Authors: Agostini, Marco Traldi, Pietro Hamdan, Mahmoud

Source: Cells (2073-4409). Feb2026, Vol. 15 Issue 3, p239. 20p.